Darrell Ragland, MD
Family Medicine · Jonesboro, ARNPI 1912960238
Payments from drug & device makers
Across 437 payments — averaging $14.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Pfizer$1K
- AstraZeneca$834
- GSK$598
- AbbVie$339
- Amgen$300
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,25498%
- Education$1192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 72 | $1,035 |
| Pfizer | 76 | $1,017 |
| AstraZeneca | 42 | $834 |
| GSK | 45 | $598 |
| AbbVie(2 entities) | 20 | $339 |
| Amgen | 23 | $300 |
| Lilly USA, LLC | 20 | $289 |
| Merck | 24 | $254 |
| Astellas Pharma US Inc | 11 | $218 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $193 |
| Boehringer Ingelheim | 15 | $184 |
| Johnson & Johnson | 12 | $148 |
| E.r. Squibb & Sons, L.L.C. | 9 | $130 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $124 |
| Abbott | 7 | $116 |
| Bayer | 7 | $109 |
| Shire North American Group Inc | 4 | $59 |
| Phathom Pharmaceuticals, Inc. | 4 | $46 |
| Novartis | 3 | $38 |
| Mylan Specialty L.p. | 3 | $36 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Edwards Lifesciences | 1 | $30 |
| Genentech USA, Inc. | 2 | $27 |
| Amarin Pharma, Inc. | 2 | $26 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Nalpropion Pharmaceuticals LLC | 2 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Corium, LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,373 in reported general payments places this provider in the 85th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 179 | $196,056 |
| JardianceEmpagliflozin | 204 | $172,765 |
| MounjaroTirzepatide | 118 | $122,421 |
| EliquisApixaban | 163 | $117,217 |
| FarxigaDapagliflozin Propanediol | 101 | $73,425 |
| XareltoRivaroxaban | 58 | $47,316 |
| MyrbetriqMirabegron | 53 | $33,406 |
| JanuviaSitagliptin Phosphate | 18 | $21,280 |
| LinzessLinaclotide | 18 | $13,702 |
| EntrestoSacubitril/Valsartan | 14 | $10,292 |
| Potassium Chloride | 487 | $9,610 |
| Atorvastatin Calcium | 959 | $8,442 |
| Pregabalin | 62 | $8,296 |
| RestasisCyclosporine | 12 | $8,172 |
| Losartan Potassium | 911 | $7,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,035 | $196,056179 claims |
| Boehringer IngelheimJardiance, Glyxambi | $184 | $179,627216 claims |
| Lilly USA, LLCMounjaro | $289 | $122,421118 claims |
| PfizerEliquis, Premarin | $1,017 | $120,552184 claims |
| AstraZenecaFarxiga | $834 | $73,425101 claims |
| Johnson & JohnsonXarelto | $148 | $47,31658 claims |
| Astellas Pharma US IncMyrbetriq | $218 | $33,40653 claims |
| AbbVieLinzess, Restasis | $339 | $21,87430 claims |
| MerckJanuvia | $254 | $21,28018 claims |
| NovartisEntresto | $38 | $10,29214 claims |
| GSKAnoro Ellipta | $598 | $4,88111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Jonesboro
- Christopher BrownJonesboro$160K
- Wallace HokeJonesboro$16K
- Timothy ShownJonesboro$14K
- Randall CarltonJonesboro$13K
- Trent LambJonesboro$13K
- Jeffery BarberJonesboro$12K
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.